Akèy › Kansè nan tete › Virginia
Etid klinik pou Kansè nan tete nan Virginia
77 etid pou Kansè nan tete ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
- Arlington46 etid
- Richmond26 etid
- Norfolk16 etid
- Charlottesville9 etid
- Roanoke7 etid
- Alexandria6 etid
- Winchester5 etid
- Waynesboro4 etid
- Lynchburg4 etid
- Newport News3 etid
- Fredericksburg3 etid
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Bon Secours Virginia Health System, Midlothian
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Oct 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
- Shenandoah Oncology, Winchester
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07102381A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Virginia Cancer Institute, Richmond
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, PC, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06324357Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Inova Schar Cancer Institute, Fairfax
Ap rekriteFaz 3
Laj 19 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT05856773Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- Inova Schar Cancer Institute, Fairfax
- Hampton University Proton Therapy Institute, Hampton
Ap rekriteFaz 2
Laj 50 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT01766297Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
- Shenandoah Oncology ( Site 8004), Winchester
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07060807A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Bon Secours Cancer Institute at St. Francis ( Site 0048), Midlothian
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005), Roanoke
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Inova Schar Cancer Institute ( Site 0025), Fairfax
- Bon Secours St. Francis Medical Center-Oncology Research ( Site 0015), Midlothian
- VCU Health Adult Outpatient Pavillion ( Site 0070), Richmond
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Charlottesville
- Research Site, Fairfax
- Research Site, Midlothian
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07007559Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Fort Belvoir
- Clinical Trial Site, Midlothian
- Clinical Trial Site, Norfolk
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Inova, Fairfax
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab
- Adult Outpatient Pavilion, Richmond
- Cellular Immunotherapies and Transplant Department, Richmond
- VCU Health at Stony Point, Richmond
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07426913A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- Next Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Fanm · Mizajou Sep 21, 2026 · NCT07524855ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Bon Secours Cancer Institute at Memorial Regional, Mechanicsville
- Bon Secours St. Francis Medical Center, Midlothian
- Bon Secours Cancer Institute at St. Mary's, Richmond
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Inova Schar Cancer Institute, Fairfax
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Newport News
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06797635Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- NEXT Oncology, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06440005Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Virginia Cancer Institute, Norfolk
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05386108A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Midlothian
Ap rekriteFaz 3
Laj 18 a 130 · Tout sèks · Mizajou Sep 8, 2026 · NCT07647328A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07100106Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Virginia Cancer Specialists-Fairfax, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07287917Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Next Oncology, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT05315700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Virginia Cancer Specialists, PC, Fairfax
- Virginia Oncology Associates, Norfolk
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06982521A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07287995The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- ak 5 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Kaiser Permanente-Burke Medical Center, Burke
- University of Virginia Cancer Center, Charlottesville
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- ak 12 plis
Ap rekriteFaz 3
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Hematology-Oncology Associates of Fredericksburg, Inc, Fredericksburg
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07383506Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.